A biomarker-driven patient-selection/response hypothesis: CTSS-high smoldering MS patients (defined by elevated CSF CTSS activity and/or a CTSS-generated MHC-II peptide signature in CSF immunopeptidomics, plus rim+ lesions on susceptibility-weighted MRI) will preferentially respond to CTSS-targeted therapy with aripiprazole-class CTSS binders, measured by reduction in CSF CTSS activity and decreased intrathecal T-cell activation markers (e.g., soluble CD27, CXCL13) without requiring 5‑HT1A receptor engagement. Testability: (i) establish threshold cutoffs for “CTSS-high” using activity-based probes or fluorogenic substrates, (ii) correlate baseline CTSS biomarkers with ex vivo microglial antigen-presentation inhibition by drug, (iii) prospective stratified pilot showing biomarker-linked response.
Adversarial Debate Score
50% survival rate under critique
Expert panel critique
Independent views, each critiquing the hypothesis on its own — the score rewards genuine disagreement and discounts consensus.
Supporting Research Papers
- TDP-43 pathology induces CD8+ T cell activation through cryptic epitope recognition
Aggregation and nuclear depletion of the RNA binding protein TDP-43 are the crucial pathological features of amyotrophic lateral sclerosis (ALS) and inclusion body myositis (IBM), two degenerative dis...
- Machine Learning for analysis of Multiple Sclerosis cross-tissue bulk and single-cell transcriptomics data
Multiple Sclerosis (MS) is a chronic autoimmune disease of the central nervous system whose molecular mechanisms remain incompletely understood. In this study, we developed an end-to-end machine learn...
- IL-10 rs1800896 polymorphism predicts biochemical remission in IBD patients undergoing biologic therapy
Background. Genetic factors, including single-nucleotide polymorphisms (SNPs), may modulate disease course and therapeutic efficacy in patients with inflammatory bowel disease (IBD). Aim. We investiga...
- Transcriptomic Models for Immunotherapy Response Prediction Show Limited Cross-cohort Generalisability
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy; yet substantial proportion of patients exhibit intrinsic or acquired resistance, making accurate pre-treatment response prediction ...
- SPYCE: A Doubly Robust Estimator for Trials Targeting Early Huntington Disease under Outcome-Dependent Censoring
Clinical trials for neurodegenerative diseases must identify sensitive endpoints -- outcomes that change rapidly enough to detect treatment effects. In Huntington disease, this requires measuring how ...
Computational Result
An LLM's reading of the literature — not computational verification.
CTSS-targeted therapy shows potential but lacks definitive clinical validation.
Method: literature_meta · Result: inconclusive · Confidence: 60%
Formal Verification
Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.